Navigation

Myelofibrosis (splenomegaly, symptoms) - ruxolitinib [ID510]

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis

Status: History
Expected date of issue: June 2013
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: Melinda Goodall
Communications manager: Shalu Kanal
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 28 September 2012
1st appraisal committee meeting: 15 January 2013
2nd appraisal committee meeting 13 March 2013
Top


 

Consultees and commentators

Consultees

 

Commentators

 

Manufacturers/sponsors

  • Novartis (ruxolitinib)

Patient/carer groups

  • Leukaemia CARE
  • MPD Voice
  • Rarer Cancers Foundation

Professional groups

  • British Committee for Standards in Haematology
  • British Society for Haematology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Greater Manchester PCT cluster
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

  • MRC Clinical Trials Unit

Evidence Review Group

  • NHS Centre for Reviews & Dissemination and Centre for Health Economics - York
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

 

Top


 

Key documents

This page was last updated: 25 June 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.